Insulin degludec - Diabetes Mellitus
You are here : Home > Formulary Search > Insulin degludec - Diabetes Mellitus
Status 1
- Cartridges
- Pre-filled pen
Documentation
PAD Profile
Other Indications
Below are listed other indications that Insulin degludec is used to treat.
- No records returned.
Other Drugs
Below are listed other drugs that are used to treat Diabetes Mellitus.
- Acarbose
- Alogliptin
- Alogliptin/metformin
- Biphasic Insulin Aspart - Novmix 30
- Biphasic Isophane Insulin - Humulin M3
- Biphasic Lispro Insulin - Humalog Mix 25
- Biphasic Lispro Insulin - Humalog Mix 50
- Canagliflozin/metformin
- Dapagliflozin
- Dapagliflozin/metformin
- Diazoxide
- Dulaglutide
- Empagliflozin
- Empagliflozin/metformin
- Ertugliflozin
- Exenatide
- Glibenclamide
- Gliclazide
- Glimepiride
- Glipizide
- Glucose
- Glyxambi (Linagliptin/empagliflozin)
- Insulin Aspart - Fiasp
- Insulin aspart - NovoRapid
- Insulin Aspart - Trurapi
- Insulin degludec with liraglutide
- Insulin detemir
- Insulin glargine - Abasaglar
- Insulin glargine - Lantus
- Insulin glargine - Semglee
- Insulin Glargine - Toujeo
- Insulin glulisine - Apidra
- Insulin Lispro - Admelog
- Insulin Lispro - Humalog
- Insulin Lispro - Lyumjev
- Insulin pump - Type 1 diabetes
- Isophane (neutral insulin) - hypurin porcine 30/70
- Isophane Insulin - Humulin I
- Isophane Insulin - Hypurin Porcine Isophane
- Isophane Insulin - Insulatard
- Linagliptin
- Linagliptin/metformin
- Liraglutide
- Metformin hydrochloride
- Metformin hydrochloride/pioglitazone
- Metformin hydrochloride/sitagliptin
- Metformin hydrochloride/vildagliptin
- Pioglitazone hydrochloride
- Repaglinide
- Saxagliptin
- Saxagliptin/dapagliflozin
- Semaglutide
- Sitagliptin
- Soluble insulin - Hypurin porcine neutral
- Soluble insulin - Actrapid
- Soluble insulin - Humulin S
- Sotagliflozin
- Suliqua (Insulin glargine/lixisenatide)
- Tirzepatide
- Tolbutamide
- Vildagliptin
Committee Recommendations (2)
MHRA Safety Alert
Cutaneous amyloidosis can be considered as a differential diagnosis to lipodystrophy when a patient presents with subcutaneous lumps at an insulin injection site. Healthcare professionals are advised to ensure that all people who inject insulin are taught to check for signs of developing cutaneous amyloidosis or lipohypertrophy and that they should report any abnormalities to their healthcare professional.
Refer to the Cutaneous amyloidosis Guidance for Healthcare Professionals below
The PCN recommends the use of Insulin Degludec (Tresiba®) in line with the policy statements below - see separate policy statements for Type I and Type II below.
Insulin Degludec (Tresiba®) will be considered as BLUE (without an information sheet) on the traffic light system.
Note added January 2025 - Prescribe on specialist recommendation only
Important - Insulin degludec is available in strengths of 100units/mL and 200units/mL - ensure correct strength is prescribed and dispensed - see MHRA Safety Update (below) for key points and practical information.